Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 4/2018

Open Access 01-04-2018 | Demyelinating Disorders (J Bernard and M Cameron, Section Editors)

Insights into the Mechanisms That May Clarify Obesity as a Risk Factor for Multiple Sclerosis

Authors: Marije J. D. Huitema, Geert J. Schenk

Published in: Current Neurology and Neuroscience Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

The proportion to which genetic and environmental factors contribute to the etiology of multiple sclerosis (MS) is still incompletely understood. An interesting association between MS etiology and obesity has recently been shown although the mechanisms underlying this association are still unknown. We propose deregulated gut microbiota and increased leptin levels as possible mechanisms underlying MS etiology in obese individuals.

Recent Findings

Alterations in the human gut microbiota and leptin levels have recently been established as immune modulators in both MS patients and obese individuals. A resemblance between pro-inflammatory bacterial profiles in MS and obese individuals was observed. Furthermore, elevated leptin levels push the immune system towards a more pro-inflammatory state and inhibit the regulatory immune response.

Summary

Deregulated gut microbiota and elevated leptin levels may explain the increased risk of developing MS in obese individuals. Further research to confirm causality is warranted.
Literature
1.
2.
3.
Stys PK, Zamponi GW, van Minnen J, Geurts JJG. Will the real multiple sclerosis please stand up. Nat Rev Neurosci. 2012;13(7):507–14.CrossRefPubMed
4.
D. W. Mielcarz and L. H. Kasper, “The Gut Microbiome in Multiple Sclerosis,” Curr Treat Options Neurol, vol. 17, no. 4. 2015.
5.
6.
Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol. 2016;36(1):103–14.PubMed
7.
Wagner NM, et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity. 2013;21(3):461–8.CrossRefPubMed
8.
9.
de Guerrero-García J, Carrera-Quintanar L, López-Roa RI, Márquez-Aguirre AL, Rojas-Mayorquín AE, Ortuño-Sahagún D. Multiple sclerosis and obesity: possible roles of adipokines. Mediat Inflamm. 2016;2016:1–24.CrossRef
10.
Bhargava P, Mowry EM. Gut Microbiome and Multiple Sclerosis. Curr Neurol Neurosci Rep. 2014;14:492.CrossRefPubMed
11.
E. M. M. Quigley, “Gut bacteria in health and disease.,” Gastroenterol Hepatol. (N. Y)., vol. 9, no. 9, pp. 560–569, 2013.
12.
Matarese G, Carrieri PB, Montella S, De Rosa V, La Cava A. Leptin as a metabolic link to multiple sclerosis. Nat Rev Neurol. 2010;6(8):455–61.CrossRefPubMed
13.
14.
Procaccini C, La Rocca C, Carbone F, De Rosa V, Galgani M, Matarese G. Leptin as immune mediator: interaction between neuroendocrine and immune system. Dev Comp Immunol. 2017;66:120–9.CrossRefPubMed
15.
Matarese G, et al. Leptin increase in multiple sclerosis associates with reduced number of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci. 2005;102(14):5150–5.CrossRefPubMedPubMedCentral
16.
Hedstrom AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler J. 2012;18(9):1334–6.CrossRef
17.
Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology. 2013;80:548–52.CrossRefPubMedPubMedCentral
18.
Munger KL, et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler J. 2013;19(10):1323–9.CrossRef
19.
• L. E. Mokry, S. Ross, N. J. Timpson, S. Sawcer, G. Davey Smith, and J. B. Richards, “Obesity and Multiple Sclerosis: A Mendelian Randomization Study,” PLoS Med., vol. 13(6), p. e1002053, 2016. Showing a significant association between a genetically determined elevated BMI and an increased risk of developing MS.
20.
Kavak K, Teter B, Hagemeier J, Zakalik K, Weinstock-Guttman B. Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Mult Scler J. 2015;21(7):858–65.CrossRef
21.
• Hedström AK, et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology. 2014;82:826–72. Showing a high impact of having the HLA-DRB1*15 allele and being obese, compared with non-obese CrossRef
22.
Tettey P, et al. Adverse lipid profile is not associated with relapse risk in MS: results from an observational cohort study. J Neurol Sci. 2014;340:230–2.CrossRefPubMed
23.
Bove R, et al. Longitudinal BMI trajectories in multiple sclerosis: sex differences in association with disease severity. In: Mult. Scler. Relat. Disord, vol. 8: Elsevier; 2016. p. 136–40.
24.
Çoban A, Çevik D, Özyurt S, Gencer M, Tüzün E, Türkoğlu R. The association between obesity and oligoclonal band formation in multiple sclerosis patients. In: Obes. Res. Clin. Pract, vol. 9: Elsevier; 2015. p. 533–5.
25.
Ochoa-Repáraz J, Mielcarz DW, Ditrio LE, Kasper LH. Role of Gut Commensal Microflora in the Development of Experimental Autoimmune Encephalomyelitis. J Immunol. 2009;183(10):6041–50.CrossRefPubMed
26.
Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci. 2011;108(Supplement_1):4615–22.CrossRefPubMed
27.
28.
29.
Y. Furusawa et al., “Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells,” Nature, vol. 0, 2013.
30.
Atarashi K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500(7461):232–6.CrossRefPubMed
31.
Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol. 2009;183(10):6251–61.CrossRefPubMed
32.
•• Mbakwa CA, et al. Gut colonization with methanobrevibacter smithii is associated with childhood weight development. Obesity. 2015;23:2508–16. This paediatric study examined the pro-inflammatory bacteria, methanobrevibacter smithii CrossRefPubMed
33.
34.
Zuo H-J, Xie ZM, Zhang WW, Li YR, Wang W, Ding XB, et al. Gut bacteria alteration in obese people and its relationship with gene polymorphism Gut bacteria alteration in obese people and its relation- ship with gene polymorphism. World J Gastroenterol. 2011;17(8):1076–81.CrossRefPubMedPubMedCentral
35.
R. Liu et al., “Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention,” Nat Med, vol. advance on, 2017.
36.
Labbé A, Ganopolsky JG, Martoni CJ, Prakash S, Jones ML. Bacterial bile metabolising gene abundance in Crohn’s, ulcerative colitis and type 2 diabetes metagenomes. PLoS One. 2014;9(12):1–17.CrossRef
37.
38.
• S. Jangi et al., “Alterations of the human gut microbiome in multiple sclerosis,” Nat Commun., vol. 7, p. 12015, Jun. 2016. Found an altered variety of gut microbal genera in treated and untreated MS patients, compared with healthy controls.
39.
Miyake S, et al. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLoS One. Sep. 2015;10(9):e0137429.CrossRefPubMedPubMedCentral
40.
•• J. Chen et al., “Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls,” Sci Rep., vol. 6, no. 1, p. 28484, Sep. 2016. This study provides an extensive number of gut microbiota species, comparing RRMS with age- and gender matched healthy controls.
41.
Balamurugan R, et al. Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children. Br J Nutr. Feb. 2010;103(3):335–8.CrossRefPubMed
42.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature. 2006;444:1022–3.CrossRefPubMed
43.
Ignacio A, et al. Correlation between body mass index and fecal microbiota from children. Clin Microbiol Infect. 2015;22(3):1–8.
44.
Million M, et al. Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. Int J Obes. 2013;3720:1460–6.CrossRef
45.
Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol. 2004;55(3):410–7.CrossRefPubMed
46.
F. Gilli et al., “Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis,” PLoS One, vol. 5, no. 1, p. e8962, 2010.
47.
Bang C, Weidenbach K, Gutsmann T, Heine H, Schmitz RA. The intestinal archaea methanosphaera stadtmanae and methanobrevibacter smithii activate human dendritic cells. PLoS One. 2014;9(6):e99411.CrossRefPubMedPubMedCentral
48.
Derrien M, et al. Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila. Front Microbiol. 2011;2(166):1–14.
49.
Säemann MD, et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J. 2000;14(15):2380–2.CrossRefPubMed
50.
Machiels K, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–83.CrossRefPubMed
51.
M. Murri et al., “Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study,” BMC Med, vol. 11, no. 46, 2013.
52.
Maffei M, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995;1(11):1155–61.CrossRefPubMed
53.
Kraszula Ł, Jasińska A, Eusebio M-O, Kuna P, Głąbiński A, Pietruczuk M. Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. Neurol Neurochir Pol. 2012;46(1):22–8.PubMed
54.
Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939–49.CrossRefPubMed
55.
De Rosa V, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity. 2007;26(2):241–55.CrossRefPubMed
56.
Moraes-Vieira PMM, et al. Leptin modulates allograft survival by favoring a Th2 and a regulatory immune profile. Am J Transplant. 2013;13(1):36–44.CrossRefPubMed
57.
Bahrami E, et al. Leptin hormone level in serum of opticospinal, neuromyelitisoptica and multiple sclerosis patients. Clin Exp Neuroimmunol. 2014;5(1):77–83.CrossRef
58.
Galgani M, et al. Leptin Modulates the Survival of Autoreactive CD4+ T Cells through the Nutrient/Energy-Sensing Mammalian Target of Rapamycin Signaling Pathway. J Immunol. 2010;185(12):7474–9.CrossRefPubMed
59.
S. Emamgholipour, S. M. Eshaghi, A. Hossein-nezhad, K. Mirzaei, Z. Maghbooli, and M. A. Sahraian, “Adipocytokine profile, cytokine levels and Foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease,” PLoS One, vol. 8, no. 10, 2013.
60.
Evangelopoulos ME, Koutsis G, Markianos M. Serum leptin levels in treatment-naive patients with clinically isolated syndrome or relapsing-remitting multiple sclerosis. Autoimmune Dis. 2014;2014:1–6.CrossRef
61.
Rotondi M, et al. Severe disability in patients with relapsing-remitting multiple sclerosis is associated with profound changes in the regulation of leptin secretion. Neuroimmunomodulation. 2013;20(6):341–7.CrossRefPubMed
62.
63.
Frisullo G, et al. The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2007;192(1–2):174–83.CrossRefPubMed
64.
J. D. J. Guerrero-García, L. Carrera-Quintanar, R. I. López-Roa, A. L. Márquez-Aguirre, A. E. Rojas-Mayorquín, and D. Ortuño-Sahagún, “Multiple sclerosis and obesity: possible roles of adipokines,” Mediators of Inflammation, vol. 2016. 2016.
65.
Reyes M, Quintanilla C, Burrows R, Blanco E, Cifuentes M, Gahagan S. Obesity is associated with acute inflammation in a sample of adolescents. Pediatr Diabetes. 2015;16(2):109–16.CrossRefPubMed
66.
Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394(6696):897–901.CrossRefPubMed
67.
Ochoa-Repáraz J, et al. Central nervous system demyelinating disease protection by the human commensal bacteroides fragilis depends on polysaccharide A expression. J Immunol. 2010;185(7)
68.
69.
W. J. van den Hoogen, J. D. Laman, and B. A. t’Hart, “Modulation of multiple sclerosis and its animal model experimental autoimmune encephalomyelitis by food and gut microbiota,” Front. Immunol., vol. 8, no. 2017.
70.
71.
Le Chatelier E, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–6.CrossRefPubMed
Metadata
Title
Insights into the Mechanisms That May Clarify Obesity as a Risk Factor for Multiple Sclerosis
Authors
Marije J. D. Huitema
Geert J. Schenk
Publication date
01-04-2018
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 4/2018
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-018-0827-5

Other articles of this Issue 4/2018

Current Neurology and Neuroscience Reports 4/2018 Go to the issue

Pediatric Neurology (WE Kaufmann, Section Editor)

Transition of Children with Neurological Disorders

Neuro-Oncology (LE Abrey, Section Editor)

When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM

Movement Disorders (S Fox, Section Editor)

Mild Cognitive Impairment in Parkinson’s Disease—What Is It?

Epilepsy (CW Bazil, Section Editor)

Prognostic Value of EEG in Patients after Cardiac Arrest—An Updated Review

Infection (J Halperin, Section Editor)

Coccidioidal Meningitis: A Review on Diagnosis, Treatment, and Management of Complications